Monday, October 10, 2016

Cream of Magnesia BP (Boots Company plc)





1. Name Of The Medicinal Product



Cream of Magnesia BP


2. Qualitative And Quantitative Composition










Active ingredient




% w/v




Light magnesium oxide




5.98




Magnesium sulphate




0.075



3. Pharmaceutical Form



A white emulsion.



4. Clinical Particulars



4.1 Therapeutic Indications



For the relief of indigestion and constipation.



4.2 Posology And Method Of Administration



As an antacid



Adults and children over 12 years: 5 to 10ml (1 to 2 teaspoonfuls)



Children 6 to 12 years: 2.5 to 5 ml (0.5 to 1 teaspoonful) according to age.



These doses should be taken in a little water after meals or when required.



Elderly: Dosage may need to be reduced.



As a laxative



Adults and children over 12 years: 25 to 50ml (5 to 10 teaspoonfuls).



Children 6 to 12 years: 5 to 15ml (1 to 3 teaspoonfuls) according to age.



These doses should be taken in a little warm water at bedtime.



Children up to 6 years: As recommended by the doctor.



Elderly: Dosage may need to be reduced.



For oral administration.



4.3 Contraindications



Hypersensitivity to any of the ingredients.



4.4 Special Warnings And Precautions For Use



Caution should be exercised in the elderly and in patients with renal impairment.



Laxatives should not be taken where there is severe abdominal pain or used regularly for prolonged periods, except on medical advice.



If symptoms persist consult your doctor.



Keep all medicines out of the reach of children.



4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction



Cream of magnesia may interfere with the absorption of cimetidine, diflunisal, digoxin, indomethacin, iron salts and tetracyclines. Absorption of buffered or enteric coated aspirin is increased by simultaneous administration of antacids. Blood concentrations of salicylates will be reduced by antacid-induced changes in urinary pH, increasing urinary excretion.



4.6 Pregnancy And Lactation



There is no adequate human data from the use of magnesium oxide and magnesium sulphate in pregnant women.



Studies in animals have not been done.



Caution should therefore be exercised when taken by pregnant women.



Although some magnesium may be secreted in breast milk, the concentration is too small to be harmful.



4.7 Effects On Ability To Drive And Use Machines



No adverse effects known.



4.8 Undesirable Effects



May cause diarrhoea. In patients with impaired renal function there may be sufficient accumulation of magnesium to produce toxic effects.



4.9 Overdose



Symptoms of overdosage include gastrointestinal irritation and watery diarrhoea. Severe poisoning may produce hypermagnesaemia, symptoms of which include nausea, vomiting, flushing, thirst hypotension, drowsiness, confusion, loss of tendon reflexes, muscle weakness, respiratory depression, cardiac arrhythmias, coma and cardiac arrest.



Treatment consists of intravenous administration of calcium gluconate injection 10% in a dose of 10-20ml to counteract respiratory depression or heart block if renal function is normal, adequate fluids should be given to assist removal of magnesium from the body. Dialysis may be necessary in patients with renal impairment or severe hypermagnesaemia.



5. Pharmacological Properties



5.1 Pharmacodynamic Properties



Magnesium hydroxide has antacid and laxative properties.



Magnesium sulphate has saline laxative properties.



5.2 Pharmacokinetic Properties



Magnesium hydroxide reacts rapidly with gastric acid to form magnesium chloride. Approximately 15-30% of the magnesium chloride formed is absorbed from the small intestine and is rapidly excreted by the kidneys in patients with normal renal function. Approximately 15-30% of an orally administered dose of magnesium sulphate is absorbed from the small intestine.



5.3 Preclinical Safety Data



Not applicable.



6. Pharmaceutical Particulars



6.1 List Of Excipients



Chloroform



Purified water



6.2 Incompatibilities



None stated.



6.3 Shelf Life



36 months.



6.4 Special Precautions For Storage



Protect from freezing.



6.5 Nature And Contents Of Container



A white or amber glass bottle having an aluminium pilfer-proof cap with flowed-in PVC liner or an expanded polyethylene liner or with an unlined polypropylene cap.



Pack size: 200, 500ml



Amber glass winchester having a thermoset plastic cap with a steran faced pulpboard liner.



Pack size: 2000 ml



6.6 Special Precautions For Disposal And Other Handling



Not applicable.



7. Marketing Authorisation Holder



The Boots Company PLC



1 Thane Road West



Nottingham NG2 3AA



8. Marketing Authorisation Number(S)



PL 0014/5304R



9. Date Of First Authorisation/Renewal Of The Authorisation



22 August 1990



10. Date Of Revision Of The Text



September 2002




No comments:

Post a Comment